IDEXX Laboratories, Inc. $IDXX Shares Sold by Villere ST Denis J & Co. LLC

Villere ST Denis J & Co. LLC decreased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.3% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 39,138 shares of the company’s stock after selling 3,066 shares during the period. IDEXX Laboratories makes up about 2.7% of Villere ST Denis J & Co. LLC’s investment portfolio, making the stock its 15th largest position. Villere ST Denis J & Co. LLC’s holdings in IDEXX Laboratories were worth $26,478,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in IDEXX Laboratories by 0.9% in the third quarter. Vanguard Group Inc. now owns 9,962,025 shares of the company’s stock valued at $6,364,638,000 after buying an additional 86,040 shares during the period. Bank of New York Mellon Corp raised its holdings in IDEXX Laboratories by 41.7% in the third quarter. Bank of New York Mellon Corp now owns 2,056,680 shares of the company’s stock valued at $1,313,992,000 after buying an additional 605,290 shares during the period. Invesco Ltd. raised its holdings in IDEXX Laboratories by 14.0% in the third quarter. Invesco Ltd. now owns 1,320,263 shares of the company’s stock valued at $843,503,000 after buying an additional 161,782 shares during the period. Principal Financial Group Inc. raised its holdings in IDEXX Laboratories by 16.7% in the third quarter. Principal Financial Group Inc. now owns 1,315,722 shares of the company’s stock valued at $840,638,000 after buying an additional 187,967 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after buying an additional 326,348 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In related news, EVP George Fennell sold 11,345 shares of the stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the sale, the executive vice president owned 9,823 shares in the company, valued at $6,352,730.56. This represents a 53.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Nimrata Hunt sold 1,758 shares of the stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the sale, the executive vice president owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,957 shares of company stock valued at $29,862,109 over the last quarter. Corporate insiders own 0.79% of the company’s stock.

IDEXX Laboratories Stock Performance

IDXX stock opened at $578.35 on Thursday. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23. The firm has a market cap of $45.94 billion, a P/E ratio of 44.25, a P/E/G ratio of 3.46 and a beta of 1.72. IDEXX Laboratories, Inc. has a 12-month low of $424.48 and a 12-month high of $769.98. The stock’s 50 day simple moving average is $597.21 and its 200 day simple moving average is $653.88.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.15. The business had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The business’s revenue was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 14.54 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Citigroup initiated coverage on shares of IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target on the stock. Stifel Nicolaus dropped their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. UBS Group decreased their price target on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. Weiss Ratings lowered shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, BTIG Research decreased their price objective on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $760.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.